The integration with single-cell transcriptome datasets from melanoma patients treated with ICB (anti-PD1, anti-CTLA4 and anti-CTLA4 plus anti-PD1) led to the refinement of a specific B lineage-related subtype associated with response: Plasma cells. The gene discussed is CTLA4; the disease is melanoma.